Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: rheumatologic, nutrition
- Who it enrolls
- age 18 Years to no upper limit; no BMI minimum stated; conditions: Psoriatic Arthritis (PsA)
- Interventions
- GLP-1 agonists; Nutrition Counseling
- Conditions
- Psoriatic Arthritis (PsA)
- Phase and size
- Phase 4 · 22 participants
- Dates
- Start 2026-05-01
Primary completion 2026-10-15 - Sponsor
- Medical College of Wisconsin (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Change from the baseline Minimal Disease Activity (MDA) Scores at Week 12 and 24 with GLP-1 Agonists vs Nutrition CounselingWeek 12 and 24
- Proportion of Patients who Achieve Disease Activity in Psoriatic Arthritis (DAPSA) Remission with GLP-1 Agonists Vs. Nutrition Counseling at Week 12 and 24Week 12 and 24
02Eligibility
Who can take part
Inclusion Criteria: * Adult patients (age 18 and older) who present to rheumatology clinic * Participants must be able to read, understand, and provide documented informed consent as approved by the Institutional Review Board (IRB). * Meet the Classification of Psoriatic Arthritis (CASPAR) criteria for PsA * Participants must have a Body Mass Index (BMI) of 30kg/m\^2 * Participants must be treated for PsA in accordance with guidelines * Have not achieved MDA in PsA patients * Have a minimum TJC \> 1 and SJC \> at baseline * Eligible for GLP-1 agonist treatment in accordance with Food Drug Administration (FDA) labeling as determined by the investigator. Exclusion Criteria: * Any prior use of GLP-1 agonists * Inability to provide informed consent * Current participation in another PsA study * Treatment initiation by GLP-1 agonists contraindicated by FDA * Patients with hemoglobin A1c (HbA1c) \> 10 at baseline
03Change log
Registry changes
No changes recorded since the trial was added.